Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor ...
Aug 25, 2023 · MK-0616 is an investigational, potentially first oral PCSK9 inhibitor designed to lower LDL cholesterol via the same biological mechanism as currently approved injectable PCSK9 inhibitors but in a daily pill form.
Merck bets big on oral PCSK9 inhibitor with phase 3 program
Aug 25, 2023 · Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that...
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia. This Phase 2b, randomized, double-blind, placebo-controlled, multicenter trial aimed to evaluate the efficacy and safety of MK-0616 in participants with hypercholesterolemia.
Why Merck's PCSK9 Inhibitors Are a Big Deal - Drug Hunter
Feb 25, 2022 · Merck's MK-0616 is a macrocyclic PCSK9 inhibitor with demonstrated once-daily PCSK9-lowering and LDL-cholesterol-lowering activities in a human clinical trial (<300 mg QD).
With PCSK9 pill, Merck aims to succeed where others failed
Mar 7, 2023 · Merck & Co. is betting a daily pill can work just as well as powerful cholesterol-lowering injections, revealing this week an aggressive plan to study in a series of large and expensive clinical trials an experimental drug it’s developing.
Merck's oral PCSK9 drug matches injectables in early trials
6 days ago · Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative.
A Series of Novel, Highly Potent, and Orally Bioavailable Next ...
Nov 25, 2021 · Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease.
MK-0616 - Drug Hunter
Apr 3, 2024 · Merck’s macrocyclic PCSK9 protein-protein interaction (PPI) inhibitor, MK-0616, is a once-daily PCSK9-lowering and LDL-cholesterol-lowering small molecule that has recently demonstrated antibody-like efficacy as an oral agent in the clinic.
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, …
Mar 6, 2023 · Discovered and developed by Merck, MK-0616 is an investigational, potentially first oral PCSK9 inhibitor designed to lower low density lipoprotein (LDL) cholesterol. MK-0616 is a macrocyclic peptide that binds to PCSK9 and inhibits the interaction of …
Oral PCSK9 Inhibitor Substantially Reduces Cholesterol in Phase 2 …
Mar 6, 2023 · PCSK9 inhibitors are usually taken alongside statins—the standard first-line therapy for treating high cholesterol—and can be used alone in people who cannot take statins. Results from the phase 2 trial showed MK-0616 reduced LDL cholesterol by around 60% among people taking 30 mg or 18 mg daily, compared to those taking a placebo.